​Government of India Unveils Curtain Raiser for Emerging Science, Technology and Innovation Conclave 2026

Date:

Share post:

The Government of India formally launched the curtain raiser for the upcoming Emerging Science, Technology and Innovation Conclave (ESTIC) 2026, scheduled to take place from October 27 to 29, 2026, at Bharat Mandapam, New Delhi. The landmark national event will be inaugurated by Prime Minister Narendra Modi.

​Organized under the guidance of the Office of the Principal Scientific Adviser (PSA) to the Government of India and coordinated by the Council of Scientific and Industrial Research (CSIR) alongside 13 key ministries and departments, ESTIC 2026 embodies a unified “Whole of Government” approach to advance India’s strategic research and technology ecosystem.

​Anchored by the central theme “Creative Minds CatalyzingScience, Empowering Technologies,” the conclave spans 12 interdisciplinary pillars designed to address pressing societal challenges and industrial transformation. Key thematic tracks include semiconductors, quantum communication, generative and physical AI, space exploration, deep-sea ocean sciences, clean energy systems, synthetic biology, and advanced healthcare.

​The three-day conclave features addresses by three Nobel Laureates—Prof. Joachim Frank (Chemistry, 2017), Sir Richard J. Roberts (Physiology or Medicine, 1993), and Prof. Konstantin Novoselov (Physics, 2010) alongside global technology executives and leading academic innovators. The event will host more than 3,000 delegates, spotlighting over 1,200 young researchers and innovators under age 45, while an expansive technology exhibition will feature 150 deep-tech startups and national laboratory innovations, with dedicated public access days to foster scientific engagement.

​During the conclave, the government will unveil the STI Vision Document 2047, charting an actionable, long-term roadmap to establish India as a global science and technology leader by the nation’s centenary of independence.

Written by: Pragna Biswas

Graphics by: Pramit Hazra

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related articles

​Regeneron Announces Positive Phase I/II Data for Ubamatamab in Recurrent Low-Grade Serous Ovarian Cancer Showing 73% Response Rate

Regeneron Pharmaceuticals, Inc. has shared encouraging early clinical results from an ongoing Phase I/II trial evaluating ubamatamab, its investigational...

Sun Pharma’s Leqselvi for Alopecia Areata Keeps Hair Growing for 2 Years, Long-Term Study Shows

French pharmaceutical leader Sanofi and U.S. biotechnology company Regeneron Pharmaceuticals have entered into an expanded licensing and collaboration...

Mankind Pharma Pledges ₹1 Crore Financial Support to Pilot Captain Smit Macchhar Following In-Flight Emergency

Mankind Pharma Ltd has announced a financial support package of ₹1 crore for Captain Smit Macchhar and his...

Pulse Pharmaceuticals secures Indian Patent for Clascoterobe API Manufacturing, Expanding Dermatological Innovation

Pulse Pharmaceuticals has announced a major regulatory and research milestone, securing an Indian patent for the process manufacturing...